Characteristics of race/ethnicity in trials leading to anti ‐rheumatic drug approval for inflammatory arthritis by the US Food and Drug Administration
ConclusionsDespite many efforts to eliminate racial/ethnic disparities, the Black was consistently underrepresented in pivotal clinical trials compared to the 2020 US national race/ethnicity distribution data. The White was consistently overrepresented, and the Hispanic presented heterogeneous results. No evident time trend was observed.
Source: International Journal of Rheumatic Diseases - Category: Rheumatology Authors: Yan Xie,
Yang Liu,
Yunhe Qin,
Xiaoyuan Chen,
Qibing Xie Tags: ORIGINAL ARTICLE Source Type: research
More News: Arthritis | Clinical Trials | Databases & Libraries | Psoriatic Arthritis | Rheumatoid Arthritis | Rheumatology